Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Berettyoujfalu – page 49

650 clinical trials in Berettyoujfalu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Berettyoujfalu at a glance
650
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

650 trials in Berettyoujfalu

Open in trial search

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effects of Favezelimab and Pembrolizumab for Patients with Blood Cancers

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Constipation

Not recruiting

Study on Linaclotide for Treating Functional Constipation in Children Aged 6 Months to Less Than 2 Years

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Linaclotide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
  • Sponsor:Leo Pharma A/S

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study on Venetoclax, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Asthma

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Uncontrolled Asthma on Inhaled Corticosteroid and Long-Acting Beta2-Agonist Therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Berettyoujfalu

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on primary prevention of atherosclerotic cardiovascular disease (ASCVD). The research examines advanced therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.

  • Cardiovascular Event Prevention
  • High-Risk Patient Management
  • Atherosclerosis Prevention

This groundbreaking research aims to evaluate new therapeutic strategies for improving cardiovascular outcomes in preventive cardiology, particularly focusing on patients who haven't yet experienced a cardiovascular event.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.